Ewan Birney, Rolf Apweiler
Ewan Birney and Rolf Apweiler have been appointed joint directors of the European Molecular Biology Laboratory – European Bioinformatics Institute (EMBL-EBI). They willl take over from Janet Thornton who is stepping down after holding the post for 14 years.
Birney and Apweiler will assume their new roles on July 1. As co-directors, they will share responsibility for all aspects of EMBL-EBI, including services, research, training, industry engagement, and European coordination. Birney and Thornton will also continue to lead their respective research groups.
Apweiler has a doctorate in biology from the University of Heidelberg. He joined EMBL in 1987 to work on the Swiss-Prot protein sequence database and became leader of the Swiss-Prot group at EMBL-EBI in 1994. He and Birney jointly led the protein and nucleotide data resources at EMBL-EBI from 2007 to 2012 and were responsible for the delivery of bioinformatics services as joint associate directors from 2012. Apweiler is actively involved in many international initiatives, including the Human Proteome Organization and the Proteomics Standards Initiative, which he chaired from 2002 to 2005.
Birney completed his doctorate at the Wellcome Trust Sanger Institute in 2000. In addition to playing a vital role in annotating the genomes of human, mouse, chicken, and other organisms, he led the analysis group for the ENCODE project. His research interests include functional genomics, assembly algorithms, statistical methods to analyze genomic information, and compression of sequence information.
David Teitel is transitioning from his role as CFO and treasurer of Alere into a new role at the company, Alere said in a document filed with the US Securities and Exchange Commission. His new role has not yet been defined. Alere has engaged an executive search firm to find his replacement, and Teitel will remain as CFO until the process is completed. Teitel joined Alere in 2003 as director of finance operations and became vice president of finance the following year. Since 2006 he has been CFO, SVP, and treasurer of Alere.
Glenn Braunstein is Pathway Genomics' new chief medical officer, where he will oversee the company’s pharmacogenomics testing menu.
Previously, Braunstein was VP of clinical innovation and director of the thyroid cancer program atCedars-SinaiMedicalCenter, where he also chaired the department of medicine. He was also the vice chair of the department of medicine at the David Geffen School of Medicine at the University of California, Los Angeles.
Richard Rew, Randall Myers
Luminex has appointed Richard Rew as SVP, general counsel and corporate secretary, effective March 4, and Randall Myers as SVP, global manufacturing and quality, effective March 16.
Prior to joining Luminex, Rew served as SVP, general counsel, and secretary at ArthroCare, which was acquired by Smith & Nephew last year. Myers retired from Applied Materials in 2012 and has since served as a consultant on supply chain and manufacturing operations.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.